Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4X1P

The crystal structure of mupain-1-17 in complex with murinised human uPA at pH4.6

Summary for 4X1P
Entry DOI10.2210/pdb4x1p/pdb
Related4N1Q 4N1R 4N1S 4X0W 4X1N
DescriptorUrokinase-type plasminogen activator, MUPAIN-1-17, SULFATE ION, ... (6 entities in total)
Functional Keywordsserine protease, peptidic inhibitor, upa, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological sourceHomo sapiens (Human)
More
Cellular locationSecreted: P00749
Total number of polymer chains2
Total formula weight29594.64
Authors
Jiang, L.,Zhao, B.,Xu, P.,Andreasen, P.,Huang, M. (deposition date: 2014-11-25, release date: 2015-10-21, Last modification date: 2017-10-18)
Primary citationJiang, L.,Zhao, B.,Xu, P.,Srensen, H.P.,Jensen, J.K.,Christensen, A.,Hosseini, M.,Nielsen, N.C.,Jensen, K.J.,Andreasen, P.A.,Huang, M.
Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues.
Int.J.Biochem.Cell Biol., 62:88-92, 2015
Cited by
PubMed Abstract: Two isomeric piperidine derivatives (meta and para isomers) were used as arginine mimics in the P1 position of a cyclic peptidic inhibitor (CPAYSRYLDC) of urokinase-type plasminogen activator. The two resulting cyclic peptides showed vastly different affinities (∼70 fold) to the target enzyme. X-ray crystal structure analysis showed that the two P1 residues were inserted into the S1 specificity pocket in indistinguishable manners. However, the rest of the peptides bound in entirely different ways on the surface of the enzyme, and the two peptides have different conformations, despite the highly similar sequence. These results demonstrate how the subtle difference in P1 residue can dictate the exosite interactions and the potencies of peptidic inhibitors, and highlight the importance of the P1 residue for protease inhibition. This study provides important information for the development of peptidic agents for pharmacological intervention.
PubMed: 25744057
DOI: 10.1016/j.biocel.2015.02.016
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.6 Å)
Structure validation

226707

數據於2024-10-30公開中

PDB statisticsPDBj update infoContact PDBjnumon